Novotech Honored with Frost & Sullivan’s 2024 Best Practices Company of the Year Award for Leadership in Biotech CRO Services
10.9.2024 22:20:00 EEST | Business Wire | Press release
Novotech, the global full-service clinical Contract Research Organization (CRO), is proud to announce that it has been awarded the prestigious 2024 Global Company of the Year Award by Frost & Sullivan. This recognition underscores Novotech’s commitment to accelerating clinical development for biotech companies through innovative solutions, advanced analytics, and a comprehensive global reach.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240910876910/en/
(Graphic: Business Wire)
Frost & Sullivan’s award honors Novotech’s innovative full-service approach that accelerates clinical development through advanced analytics, access to diverse patient populations, and through specialized technology.
“Overall, Novotech distinguishes itself in the ever-expanding CRO market by successfully addressing the complex regulatory landscape with a deep understanding of local regulations and overcoming cultural barriers to establish itself as a truly global CRO. As a result, the company progresses closer to becoming a preferred global partner with regional leadership and localized expertise,” said Unmesh Lal, Global Research Director at Frost & Sullivan.
Unmatched Global Reach and Expertise
Novotech's extensive global footprint allows the company to provide tailored solutions that address the unique regulatory and cultural nuances of each market. This strategic advantage facilitates faster patient recruitment and enhanced trial efficiency, ensuring successful outcomes for its biotech clients. Novotech's project manager-centric model ensures seamless communication and effective execution of clinical trials, fostering strong, collaborative relationships with clients.
Commitment to Innovation and Advanced Technology
A key element in being awarded this accolade is Novotech continuing to leverage cutting-edge technology to enhance clinical trial operations. The company's ongoing investments in artificial intelligence (AI), big data analytics, digital clinical trials, and cloud-based software platforms significantly improve data quality, trial planning, and transparency in communications with stakeholders. Partnerships with industry leaders like Veeva and Medidata further empower Novotech’s clients to optimize their drug development programs.
Recognition of Excellence
Frost & Sullivan first recognized Novotech with their award for best APAC CRO in 2006, and Novotech has continued to win this award every year since. Receiving, for the first time, Frost & Sullivan’s 2024 Global Company of the Year Award is tangible evidence of Novotech’s drive for constant improvement and creating optimal outcomes for our partners and clients.
“We are honored to receive the 2024 Global Company of the Year Award from Frost & Sullivan,” said Dr. John Moller, CEO of Novotech. “This recognition is a testament to the hard work and dedication of our team, our commitment to innovation, and our unwavering focus on delivering exceptional results for our biotech and pharmaceutical clients. We are proud to be at the forefront of advancing clinical development and to be acknowledged as a leader in the CRO industry.”
Frost & Sullivan Best Practices Awards recognize companies in various regional and global markets for demonstrating outstanding achievement and superior performance in leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry.
About NovotechNovotech-CRO.com
Founded in 1997, Novotech is a global full-service clinical Contract Research Organization (CRO) focused on partnering with biotech companies to accelerate the development of advanced and novel therapeutics at every phase.
Recognized for its industry-leading contributions, Novotech has received numerous prestigious awards, including the CRO Leadership Award 2023, the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence 2023, the Asia-Pacific Contract Research Organization Company of the Year Award since 2006.
The Company offers a comprehensive suite of services including laboratories, Phase I facilities, drug development consulting, regulatory expertise, and has experience with over 5,000 clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. With a presence in 34 office locations and a dedicated team of 3,000+ professionals worldwide, Novotech is a trusted end-to-end strategic partner of choice.
For more information or to speak to an expert team member visit www.Novotech-CRO.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20240910876910/en/
Contacts
Media
Toyna Chin
mediacontact@novotech-cro.com
USA: +1 415 364 8135
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting Strengthens Capabilities with Addition of Lukkap31.3.2026 16:30:00 EEST | Press release
Andersen Consulting adds collaborating firm Lukkap, a consultancy focused on experience-driven capabilities aligned with clients’ evolving people, customer, and digital transformation needs. Founded in 2009 and headquartered in Spain, Lukkap delivers integrated solutions that help organizations transform how they serve customers, engage employees, and unlock value through behavioral insights and data analytics. The firm’s multidisciplinary approach spans customer journey redesign, high-impact employee experience programs, talent and leadership development, predictive analytics, and comprehensive outplacement and transition services. Lukkap works across sectors — including healthcare, pharmaceutical, consumer goods, retail, finance, and banking — to build human-centered strategies that drive measurable business results. “By combining our experience-led methodology with Andersen Consulting’s global platform, we can accelerate the way organizations approach customer experience,” said Albe
Sub-Q Bionics Closes $1.5M Pre-Seed Round to Advance Next-Generation Solution for Lymphedema Care31.3.2026 16:26:00 EEST | Press release
Sub-Q Bionics, a medical device company developing next-generation solutions to improve care for patients living with lymphedema, today announced the successful close of its $1.5 million pre-seed funding round. The round includes investment from Mayo Clinic and Yeda, the technology transfer company of the Weizmann Institute of Science, as well as several private investors. The Israel Innovation Authority also provided matching funds. The funding will enable Sub-Q Bionics to continue to develop its novel bionic lymph node technology designed to transform how lymphedema is managed, based on scientific innovations from the Weizmann Institute and Shamir Medical Center. The system aims to provide a solution to manage fluid with a subcutaneous implant that will allow patients freedom of movement, automatic fluid management and reduction of symptoms such as pain and swelling. Lymphedema affects millions of patients worldwide, especially breast cancer survivors, and remains significantly under
HTEC Achieves SOC 2 Type II Attestation, Reinforcing Commitment to Client Trust31.3.2026 16:25:00 EEST | Press release
HTECtoday announced that it has successfully achieved a SOC 2 Type II attestation, audited by Deloitte, demonstrating the company’s commitment to maintaining high standards in security, availability, and confidentiality. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260331132225/en/ HTEC today announced that it has successfully achieved a SOC 2 Type II attestation, audited by Deloitte, demonstrating the company’s commitment to maintaining high standards in security, availability, and confidentiality. For clients, this means working with a technology partner whose practices are standardized, consistently executed, and independently verified over time. It reflects a level of operational maturity where security, reliability, and data protection are built into every engagement. Achieving this standard required coordinated effort across the entire organization. Compliance, engineering, delivery, security, IT, legal, and people t
Impartner Redefines Partner Marketing Automation with Full Automation, AdTech and AI to Drive Measurable Revenue31.3.2026 16:00:00 EEST | Press release
Impartner, the world’s leading partner revenue orchestration platform, today announced a major advancement that unifies partner marketing automation within the platform, powered by full automation, AdTech and AI to turn partner marketing into measurable revenue. As partner ecosystems expand across regions, marketplaces and multi-tier models, marketing execution has often remained fragmented. Impartner eliminates those gaps by unifying recruitment, enablement, campaign automation and performance tracking within a single operational system, making partner demand generation and marketing fully operational, measurable, and scalable across all partner interactions. “What makes partner marketing successful is not content distribution, it’s execution, scale and measurable pipeline and revenue,” said Emile van de Klok, Senior Director of Channel Marketing Solutions at Impartner. “By redefining partner marketing automation and embedding it directly into our revenue orchestration platform, we en
Lotte Rental Speeds Growth and Innovation with Multiyear Partnership with Rimini Street31.3.2026 16:00:00 EEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™, and the leading third-party support provider for Oracle, SAP and VMware software, today announced that Lotte Rental, South Korea’s leading car rental company, has selected Rimini Street to provide support for its Oracle and SAP systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260331863399/en/ Lotte Rental Speeds Growth and Innovation with Multiyear Partnership with Rimini Street A leader in the rental industry for over 40 years, Lotte Rental operates 300 branches across Korea and subsidiaries in Thailand and Vietnam and offers car sharing and used car sales. To drive its vision of accelerating growth and staying ahead in the mobility industry, the company has restructured its IT systems and invested in next-generation technology to power innovation and support its strategic expansion plans. Cost Savings and System Stability Fuel Inno
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom